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Summary
‘Symptoms’ is a core outcome domain for atopic eczema (AE) trials, agreed by consensus
as part of the Harmonising Outcome Measures for Eczema (HOME) initiative. To stan-
dardize and validate the core domain symptoms and symptom instruments for AE trials
the HOME roadmap is followed. Its first step is to establish if and how symptoms have
been measured in published AE treatment trials. Therefore the Global Resource for
Eczema Trials database was used to collect all randomized controlled trials (RCTs) of
treatments for AE between January 2000 and April 2014. Study selection and data extrac-
tion were performed by three reviewers independently. We identified the use of symp-
toms in 295 of 378 trials (78%). Symptoms as a primary end point were applied by 147
RCTs (50%). Seventeen different symptoms were measured, but mostly itch and sleep
loss. Symptoms were assessed by only 37% of trials by a stand-alone symptom measure-
ment. Overall 63% of RCTs used a composite instrument, and 30 different instruments
were identified. The Scoring Atopic Dermatitis (SCORAD) index was the most commonly
applied, but only 23% of RCTs reported the SCORAD symptom score separately. This
systematic review demonstrates that symptoms, most frequently itch and sleep loss, are
commonly reported in AE treatment trials, but are measured using many different
instruments. Often symptoms are evaluated as part of a composite instrument, and
currently it is not possible to extract symptoms-only data from most published studies.
Future trials should report symptom scores to permit meta-analysis of the core outcomes.
What’s already known about this topic?
• There is a high level of variation in outcome domains and instruments used for
atopic eczema (AE).
• Harmonization of AE instruments is necessary to allow better evidence-based clini-
cal decision making.
• The Harmonising Outcome Measures for Eczema (HOME) initiative aims to validate a
core outcome set (COS) for AE clinical trials; ‘symptoms’ is selected as one of the four
core outcome domains beside clinical signs, quality of life and long-term control.
What does this study add?
• Symptoms, most frequently itch and sleep loss, are commonly reported in AE trials,
but are often poorly measured using many different instruments and as part of a com-
posite instrument, most commonly the SCORing Atopic Dermatitis (SCORAD) index.
• Describing patient-reported symptoms and clinician-reported signs separately will
improve trial reporting and facilitate meta-analysis.
• Deployment of the COS for AE in future trials is a key requirement in moving forward.
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In order to interpret clinical studies evaluating treatments for
atopic eczema (AE; synonymous with atopic dermatitis or
eczema), results need to be comparable. Unfortunately many
different outcomes and outcome measurement instruments
(further referred to as ‘instruments’) have been used in AE
randomized controlled trials (RCTs), as shown in systematic
reviews.1–3 Therefore standardization and validation of out-
come domains and instruments is crucial.
The Core Outcome Measures in Effectiveness Trials
(COMET) initiative promotes the development and imple-
mentation of core outcome sets (COSs). COSs represent a
consensus-derived minimal set of outcomes (domains and
per domain) that should be assessed in all clinical trials.4 The
international Harmonising Outcome Measures for Eczema
(HOME) initiative has developed the HOME roadmap to
guide the consensus methodology for developing a COS for
AE trials (Fig. 1).5 The COS of four core domains has been
previously agreed for AE; these domains are clinical signs,
patient-reported symptoms, health-related quality of life and
long-term control.6
Once the domains have been identified, the next stage in
the HOME roadmap is to identify the instruments used in
RCTs to measure each domain. For the clinical signs domain,
a systematic review that identified instruments and their mea-
surement properties was carried out.3 The results were used at
a consensus meeting to agree on an instrument that should be
recommended for inclusion in the core set.7 This systematic
review was carried out to identify what instruments have been
used in RCTs to measure the domain of symptoms. A symp-
tom is defined here as a departure from normal function,
appearance or feeling that is noticed by the patient, indicating
the presence of disease or abnormality.8,9
A previous systematic review1 identified that symptoms
were reported in 86% of RCTs published between 1994 and
2001. Numerous different severity instruments, many
unnamed and unvalidated, were identified. Furthermore, while
there are many symptoms associated with AE, most RCTs mea-
sured only itch or sleep loss.
The objectives of the current systematic review were to
establish: (i) the proportion of RCTs that reported at least one
AE symptom as an outcome measure; (ii) the number and
type of AE symptoms that have been captured in these RCTs;
and (iii) the number and type of instruments used to capture
these AE symptoms.
Methods
This systematic review has been conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) statement.10 The protocol was regis-
tered on a publicly accessible website.11
Literature search
The Global Resource for Eczema Trials (GREAT) database was
used to identify all RCTs on AE treatments published since
2000, as a previous review already evaluated many RCTs
before 2000.1 The GREAT database (www.great-
database.org.uk) contains records of all RCTs of treatments for
established AE published since the inception of Medline
(1966) and Embase (1980), the Cochrane Library and the
Skin Group Specialised Register databases, plus the CINAHL,
Allied and Complementary Medicine Database and LILACS
databases from 2000 onwards.12,13 RCTs published between
January 2000 and April 2014 were included.
Eligibility criteria
RCTs evaluating AE treatments were assessed to determine
whether symptoms had been reported (either by the patient
or by proxy, i.e. by the parent, caregiver or interview). In
RCTs that reported at least one AE symptom, symptoms
could be reported either as stand-alone symptom measure-
ment (i.e. a single symptom such as itch by visual ana-
logue scale, VAS) or as part of a composite instrument
measuring more than one symptom or more than one
domain (e.g. symptoms and clinical signs). Both full-text
papers and abstracts were included. Non-English-language
RCTs were included only if an English language abstract
was available. Table 1 provides an overview of the eligibil-
ity criteria.
Study selection
Titles and abstracts were screened by three reviewers indepen-
dently (L.A.A.G., J.R.C. and N.K.R.), followed by the appraisal
of full texts for eligibility. Discrepancies were resolved by dis-
cussion within the research team.
Data extraction
A study-specific data collection form was developed to
extract relevant information. For all RCTs, data on study
characteristics and whether symptoms were reported were
extracted. For RCTs that reported symptoms, further data
were extracted on whether symptoms were the primary end
point, what instruments were used, and their characteristics
(name of instrument, symptoms assessed, other domains
assessed, type of scaling used, anchors used for interpreta-
tion). Data were extracted independently for each study by
two of the three reviewers (L.A.A.G., J.R.C. and N.K.R.).
Discrepancies were resolved by discussion within the
research team.
The individual symptoms and symptom instruments
identified were summarized qualitatively and percentages were
calculated.
Results
In total 378 RCTs were identified, of which 295 (78%)
reported symptoms of AE (Fig. 2). Symptoms were
included in the primary outcome for 147 of 295 RCTs
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(50%) and for 104 of 295 (35%) as a secondary outcome
only. For 44 RCTs (15%) the primary outcome was
unclear.
Type of symptoms reported
The type and number of symptoms captured in the RCTs
are shown in Table 2. Itch (synonym: pruritus) was the
most commonly reported symptom and was assessed in
almost all trials (289 of 295, 98%) either as a single,
stand-alone measure or as part of a composite instrument.
Itch was reported as a stand-alone symptom in 46% of
RCTs (135 of 295). Sleep loss was the second most com-
monly assessed symptom, reported in just over half of the
295 RCTs (181, 61%). Sleep loss was reported as a stand-
alone symptom in 37 of 295 RCTs (13%). Other symptoms
reported infrequently included skin dryness/roughness,
bleeding, cracking, flaking, irritation, weeping/oozing,
burning, skin appearance, erythema, scratching, pain, peel-
ing, rash and smarting.
Type of instruments used to capture symptoms
In total, 109 of 295 RCTs (37%) measured symptoms only as
a stand-alone, single outcome, and 184 of 295 RCTs (62%)
Step 3: develop core set of outcome measurement instruments 
Identification and recommendation of adequate measurement instrument(s) 
for each core outcome domain by a 5 stage process
Step 1: define scope and applicability 
Population (condition)
Setting (e.g. trial, registry, clinical practice)
Geographical/regional scope *
Stakeholders
Step 2: develop core set of outcome domains
Consensus study involving representatives of relevant 
stakeholders.  
Step 4: disseminate, review, and possibly revise  
core set of outcome measurement instruments  
Fig 1. The Harmonising Outcome Measures
for Eczema (HOME) roadmap to develop core
sets of outcome measurement instruments.
*For trials the scope should generally be
global.
Table 1 Inclusion and exclusion criteria of study selection
Inclusion criteria Exclusion criteria
Population Atopic eczema (synonyms:
eczema, atopic dermatitis,
neurodermatitis)
Study design Randomized controlled
trials evaluating treatments
Construct Symptoms Exclusively clinical
signs, quality of
life, control of
flares, biomarkers,
physiology of
the skin
Type of
instrument
Patient reported or
by proxy
Type of
publication
Full-text paper or
abstract in English
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assessed symptoms as part of a composite instrument, measur-
ing more than one symptom and/or domain.
The most commonly used measure of symptoms was the
VAS. For itch it was used in 220 of 289 RCTs (76%), and in
total, 220 of 317 times (69%), as itch was measured in more
than one way in some RCTs (i.e. by composite instrument
and stand-alone itch measure). For sleep loss it was assessed
in 162 of 181 RCTs (90%) and in total 162 of 193 times
(84%). The VAS was the most common method used for
stand-alone measurement of itch (65 of 135, 48%) and sleep
loss (18 of 37, 49%). The VAS was usually a 10-cm/100-mm
line. The numerical rating scale (NRS), usually a four-point
scale ranging from 0 to 3, and verbal rating scale (VRS),
which is an NRS associated with severity descriptions, were
the second most common methods used: itch 81 of 289 RCTs
(28%) and in total, 81 of 317 times (26%), sleep loss 21 of
181 RCTs (12%) and in total, 21 of 193 times (11%). When
measured as a stand-alone symptom, itch was measured using
NRS/VRS in 54 of 135 RCTs (40%) and sleep loss in nine of
37 RCTs (24%). Other infrequently used measures were time
Table 2 Type and number of symptoms measured in 295 randomized
controlled trials
Symptom Number (%)
Itch 289 (98)
Sleep loss 181 (61)
Skin dryness/roughness 11 (37)
Bleeding 5 (17)
Cracking 5 (17)
Flaking 5 (17)
General symptoms 5 (17)
Irritation 5 (17)
Weeping/oozing 5 (17)
Burning/stinging 4 (14)
Skin appearance 4 (14)
Erythema 3 (10)
Scratching 3 (10)
Pain 2 (07)
Peeling 1 (03)
Rash 1 (03)
Smarting 1 (03)
Id
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ﬁ
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n Records idenﬁed in: 
GREAT database (n = 383)
382 records screened aer 
removing duplicates
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g
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ty
378 full-text papers assessed 
for eligibility
87 full-text papers and abstracts 
excluded, with reasons 
- Irrelevant construct (n = 83)
295 studies included in 
qualitave analysis
In
cl
ud
ed
4 records excluded aer tle and 
abstract screening
Fig 2. Study flow diagram (according to the
Preferred Reporting Items for Systematic
Reviews and Meta-Analysis statement).
GREAT, Global Resource for Eczema Trials.
Table 3 Methods used to measure itch and sleep loss in randomized controlled trials
Method Itch (in total)a
Itch as a stand-alone
measure
Sleep loss
(in total)a
Sleep loss as a
stand-alone
measure
VAS 220/317 (69) 65/135 (48) 162/193 (84) 18/37 (49)
NRS/VRS 81/317 (26) 54/135 (40) 21/193 (11) 9/37 (24)
NRS and VAS 3/317 (1) 3/135 (2)
Time to resolution 1/317 (03) 1/135 (07)
Number of nights
lost to sleep
2/193 (1) 2/37 (5)
Actiwatch 1/193 (05) 1/37 (3)
Unclear 12/317 (4) 12/135 (9) 7/193 (4) 7/37 (19)
Values are n/N (%). a‘In total’ represents the fact that some randomized controlled trials used more than one way to measure symptoms (i.e.
by composite instrument and stand-alone measure). NRS, numerical rating scale; VAS, visual analogue scale; VRS, verbal rating scale.
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to resolution, number of nights of lost sleep and Actiwatch.
Details of the methods used to capture itch and sleep loss are
presented in Table 3.
In total, 30 composite instruments including symptoms
were used in RCTs and are presented in Table 4. Twenty com-
posite instruments combined patient-reported symptoms
scores with physicians’ clinical signs scores (171 of 295,
58%). Eighteen instruments were unnamed (60%). The num-
ber of symptoms in these instruments ranged from one to
seven, with a mean of 22 symptoms and median of 1. Symp-
toms in these instruments were mostly measured by an NRS
or VRS (20, 67%), with VAS accounting for 23% and all but
one including itch.
The most commonly used composite instrument that
included symptoms was the SCORing Atopic Dermatitis
(SCORAD) index14 (143 RCTs, 49%). The subjective compo-
nent of the SCORAD index (part C) measures the intensity of
itch and sleep loss using a patient-reported VAS. However, less
than a quarter of RCTs reported the part C symptom score
separately from the overall score (33 of 143, 23%).
The modified Eczema Area and Severity Index (EASI)15 was
the second most used composite instrument, used in seven
Table 4 Name, content and number of symptom instruments identified in 295 randomized controlled trials (RCTs)
Instrumenta
Symptoms
Itch
Sleep
loss
Dryness/
roughness Bleeding Cracking Flaking
General
symptoms Irritation
Weeping/
oozing
Burning/
stinging
ADASI20 
ADSI17 
GCS21 
mEASI15 
PAIS22 
Patient’s overall
self-assessment
score23
 
POEM16       
Rajka and
Langeland
index24

SCORAD14  
SSRI25 
SSS26 
SSS (Costa)27  
Unnamed 128  
Unnamed 229   
Unnamed 330   
Unnamed 431 
Unnamed 532 
Unnamed 633 
Unnamed 734 
Unnamed 835   
Unnamed 936   
Unnamed 1037  
Unnamed 1138 
Unnamed 1239 
Unnamed 1340   
Unnamed 1441  
Unnamed 1542 
Unnamed 1643  
Unnamed 1744 
Unnamed 1845  
aReferences are of papers where instruments were mentioned for the first time. ADASI, Atopic Dermatitis Area and Severity Index; ADSI,
Atopic Dermatitis Severity Index; GCS, Global Clinical Score; mEASI, modified Eczema Area and Severity Index; PAIS, Physician Assessment
of Individual Signs; nr, not reported; NRS, numerical rating scale; POEM, Patient-Oriented Eczema Measure; SCORAD, SCORing Atopic
Dermatitis index; SSRI, Symptom Score Reducing Index; SSS, Severity Scale Score; SSS (Costa), Simple Scoring System; VAS, visual
analogue scale; VRS, verbal rating scale.
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RCTs (24%). This instrument is a modification of the EASI
(which measures only clinical signs), and measures itch inten-
sity using a VAS, which is assessed by the patient or by proxy.
Only one RCT reported the pruritus score beside the overall
score.
Other composite instruments were the Patient-Oriented
Eczema Measure (POEM)16 and the Atopic Dermatitis Severity
Index (ADSI),17 used in five (17%) and four (14%) RCTs,
respectively. POEM is composed of seven symptoms (pruritus,
sleep disturbance, bleeding, weeping or oozing, cracking, flak-
ing, dryness or roughness), measured by frequency on a five-
point rating scale and all assessed by the patient or by proxy.
ADSI measures the intensity of clinical signs and itch, assessed
by the patient or by proxy, on a four-point rating scale. No
RCT reported the itch score of the ADSI. The remaining
instruments reported were each applied only once.
Discussion
Our results show that although symptoms are reported in most
RCTs, many of these patient-reported outcome measures
Other domains
Symptoms
measured by
Number of
symptoms
assessed
Number of
times used
in RCTs (%)
Skin
appearance Erythema Pain Peeling Smarting
Clinical
signs
Clinical
course
Quality
of life
General
disease
control NRS VRS VAS
  1 1 (03)
  1 4 (14)
  1 1 (03)
  1 7 (24)
  1 1 (03)
 nr nr nr 2 1 (03)
 7 5 (17)
  1 1 (03)
  2 143 (49)
 nr nr nr 1 1 (03)
  1 1 (03)
   2 1 (03)
  2 1 (03)
   nr nr nr 5 1 (03)
 3 1 (03)
  1 1 (03)
  1 1 (03)
  1 1 (03)
  1 1 (03)
 3 1 (03)
 3 1 (03)
  3 1 (03)
  1 1 (03)
  1 1 (03)
  4 1 (03)
   4 1 (03)
  1 1 (03)
   3 1 (03)
  1 1 (03)
  2 1 (03)
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(PROMs) are captured by the use of composite instruments that
incorporate only one or two symptoms, and often do not report
the symptom score separately. As most RCTs on AE treatments
aim to reduce symptoms and improve quality of life, which can
be determined only by the patient, assessing and reporting these
outcomes is important. Furthermore, the use of PROMs may
help to reduce the physician time in consultations and indirectly
confer health benefits by involving the patient.18
Compared with the previous systematic review,1 which
identified symptoms in RCTs between 1994 and 2001, the
reporting of symptoms in RCTs of AE treatment has changed
little. Symptoms are still reported in most RCTs (78% com-
pared with 86% previously), and itch and sleep loss remain
the most commonly reported symptoms. Other instruments
measuring symptoms have been identified in recent years, but
most remain embedded within composite instruments com-
bining symptoms scores with physicians’ clinical signs scores
(58% compared with 55% previously). Despite AE being asso-
ciated with many symptoms, the vast majority of RCTs
reported only itch and sleep loss. The question is whether
these symptoms are regarded as most relevant to patients. A
global survey of 1104 patients and carers of patients with AE
investigated the importance of symptoms of AE, like itch, in
determining treatment effect.19 Itch, pain/soreness, skin feels
hot or inflamed, bleeding, involvement of visible or sensitive
body sites, cracks, sleep difficulties, amount of body affected
and weeping were rated as being quite or very important.
Both stand-alone symptom measurements and composite
instruments often apply the NRS/VRS and VAS to measure
symptoms. Although the NRS/VRS and VAS capture mostly
the intensity/severity of symptoms, they rarely capture fre-
quency or interference with daily activities. POEM measures
frequency rather than intensity/severity to provide informa-
tion about the pattern of relapses and remissions.16 The most
utilized instrument in RCTs to measure symptoms was the
SCORAD index, which includes the measurement of two
symptoms, itch and sleep loss. The only instrument measuring
more symptoms, namely seven, and assessed by the patient or
by proxy was POEM, which was applied in only five RCTs. Of
many composite instruments, including the SCORAD index,
the symptom score was not usually reported. Without separate
symptom reporting, the results of RCTs are less meaningful, as
treatment effects cannot be compared as to their effect on
symptoms.
The next step to developing a COS is a critical appraisal of
the validation data of the identified instruments to investi-
gate whether these instruments are appropriate to use, and to
select one most appropriate instrument for the core domain
symptoms.
Strengths and limitations of this systematic review
We followed a predefined protocol and the PRISMA statement.
Our search was performed using a validated search filter.13 Two
reviewers independently extracted data for each study, and dis-
agreements or uncertainties were resolved through discussions.
There remain some potential limitations. The review
included only RCTs evaluating AE treatment(s); trials on pre-
vention are not included in the GREAT database. Secondly,
papers in languages other than English were included only if
they had an English abstract. This may have affected the
results, as sufficient details could not always be obtained from
abstracts. Thirdly, it could not always be confirmed whether
symptoms were reported by the patient or by the physician
(making it a clinical sign), and in some cases it was not clear
who had answered the question(s).
Recommendations for researchers, clinicians and
decision makers
The current review highlights the many different instruments
used to assess the core outcome domain symptoms and the
nonseparate reporting of symptom scores when they are mea-
sured by a composite instrument.
To provide better data on the effects of treatments, future
trials should present symptom scores separately where mea-
sured by a composite instrument. In addition to itch and sleep
loss, other symptoms important to patients with AE should be
reported.
In order to improve trial reporting, to facilitate meta-
analysis and to ensure that research is relevant to patients,
the validation and harmonization of instruments and imple-
mentation of PROMs in clinical trials are crucial. The adop-
tion of a minimum COS including the domains of
symptoms, clinical signs, quality of life and long-term con-
trol in all future AE clinical trials is key. Ideally one well-
validated core instrument for each domain will be used in
all future trials and the HOME initiative is moving towards
this goal.6
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